Pharming Group (NASDAQ:PHAR) today announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has granted marketing approval for Joenja (leniolisib) as the first targeted treatment for activated phosphoinositide 3-kinase delta syndrome (APDS).
Abivax (NASDAQ:ABVX) today announced its full-year 2025 financial results and provided a comprehensive corporate update, underscored by a significantly strengthened capital structure and steady clinical progress.
Pfizer (NYSE:PFE) and Valneva (NASDAQ:VALN) today announced topline results from the Phase 3 VALOR study evaluating their 6-valent OspA-based Lyme disease vaccine candidate, PF-07307405.
Avalo Therapeutics (NASDAQ:AVTX), a clinical-stage biotechnology company focused on developing interleukin-1β (IL-1β)-targeting therapies for immune-mediated inflammatory diseases, reported its financial results for the full year ended December 31, 2025.
Arbutus Biopharma (NASDAQ:ABUS) today reported a landmark set of financial and clinical results for the fourth quarter and full year ended December 31, 2025.
BioLineRx (NASDAQ:BLRX) today announced its audited financial results for the full year ended December 31, 2025, detailing a period of significant fiscal discipline and pipeline maturation.
Bausch + Lomb (NYSE:BLCO) today unveiled positive topline results from its pivotal 24-month U.S. clinical trial of the ELIOS System, an innovative, implant-free procedure designed to treat elevated intraocular pressure (IOP) in patients with open-angle glaucoma.
Viatris (NASDAQ:VTRS) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Effexor® SR (venlafaxine hydrochloride) sustained-release capsules for the treatment of adults with generalized anxiety disorder (GAD).
HUTCHMED (NASDAQ:HCM) announced the initiation of a registrational Phase III clinical trial for HMPL-760, an investigational non-covalent Bruton’s tyrosine kinase (BTK) inhibitor.
Biogen (NASDAQ:BIIB) and Eisai, today released new real-world findings from a massive U.S. claims analysis demonstrating high long-term persistence rates for patients receiving intravenous (IV) LEQEMBI® (lecanemab).
Nektar Therapeutics (NASDAQ:NKTR) will present Phase 2b clinical data for rezpegaldesleukin at the 2026 American Academy of Dermatology (AAD) Annual Meeting in Denver, the company announced.
Cellectis (NASDAQ:CLLS), a clinical-stage biotechnology company using its proprietary TALEN® gene-editing platform to develop next-generation immunotherapies, announced its financial and operational results for the fiscal year ended December 31, 2025.
